Driven by further penetration of Celgene’s Revlimid (lenalidomide) into the first-line setting and the launch of premium-priced emerging therapies, the multiple myeloma drug market will experience robust 5.6% annual growth from 2010 to 2020 in the leading markets of the USA, France, Germany, Italy, Spain, the UK and Japan, according to a new report from health care advisory firm Decision Resources.
Three agents currently dominate sales in the myeloma market: Celgene’s Revlimid, Takeda/Janssen-Cilag/Janssen’s Velcade (bortezomib), and Celgene’s Thalidomide/Thalomid and Fujimoto Seiyaku’s Thaled (thalidomide). In a report issued last year, Decision Resources forecast that the multiple myeloma market would rise from a value of $2.1 billion in 2008 to $5.3 billion in 2018.
Revlimid to eclipse Velcade
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze